Adverse Reaction to Drug, Drug-induced Disorder of Liver
Conditions
Brief summary
Drug metabolism in the liver is subject to large fluctuations (differences between women and men, people of different ethnic backgrounds, children and adults). These large differences are responsible for very different drug effects and side-effects (and especially liver damage caused by drugs) between individuals. Recent scientific findings suggest that blood derived cells can be used to model individual effects of drugs on the liver reflect inter-individual differences. Since liver damage caused by drugs is a diagnosis of exclusion, the aforementioned cells can be used to identify patients that show higher sensitivity to hepatotoxic side-effects and - in case several drugs are involved - identify the causal agent or possible interactions.
Detailed description
Drug-induced liver injury (DILI), especially its idiosyncratic for is often an unpredictable complication of drug therapy. Until now it is very challenging to predict occurrence, severity and outcome of DILI. Previous data provide evidence that cells from peripheral blood may reflect hepatocellular damage (Fannin RD, Hepatology. 2010). Own research could show that peripheral monocytes are capable to obtain several hepatocyte-like functions while maintaining individual characteristics of the donor, especially cytochrome P450 metabolism (Benesic, Gerbes, et al, Lab Invest 2012). This study investigates the effects of potentially hepatotoxic drugs on cells generated from patient blood in comparison to the clinical presentation. Its aim is the evaluation of in vitro tests using monocyte derived cells for diagnosis and exclusion of DILI and the potential to use the patient derived-cells for mechanistic investigations of DILI. 4 groups are investigated: 1) donors without liver disease 2) patients who will start a therapy with DILI-potential; 3) DILI patients; 4) patients with liver injuries other than DILI. Patient history and clinical data are obtained and a single blood sample will be collected after informed consent.
Interventions
In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
Sponsors
Study design
Eligibility
Inclusion criteria
* Age ≥ 2 years * Informed consent given by the patient or in case of inability to give informed consent informed consent of the legally nominated consultee
Exclusion criteria
* Anemia requiring blood transfusion * acute or chronic hepatitis B, C or human immunodeficiency virus infection * lack of informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reflection of individual drug hepatotoxicity in monocyte derived cells | 12 months | After blood sampling, monocyte derived cells will be generated and tested in vitro for the respective compounds in short term and up to 4 weeks. If possible, the patient will have a clinical follow up during routine care to assess liver injury , course and outcome of the disease when applicable. |
Countries
Australia, Germany, Hong Kong, Japan, South Korea